Travere Therapeutics (TVTX) Is Down 18.7% After FDA Extends FILSPARI FSGS Review Timeline – Has The Bull Case Changed?

Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS) to a new ...

Celcuity's Key Drug Candidate Nears Critical FDA Decision

The NDA submission is supported by efficacy data from the Phase 3 VIKTORIA-1 trial. Results demonstrated that in the wild-type patient cohort, the combination of gedatolisib and fulvestrant reduced ...